Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections

Journal of Chemotherapy

Volumn 8, Issue 1, 1996, Pages 55-58

  Domingo, S ^a   Gamazo, C ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Azithromycin; Brucella melitensis; Murine models

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BRUCELLA MELITENSIS; BRUCELLOSIS; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION;

EID: 0030060071     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.1.55     Document Type: Article

References (14)

1. Montejo JM, Alberola I, Glez-Zárate P, et al. Open, randomised therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993; 16:671-676.
2. Ariza J, Gudiol F, Pallarés R, Rufí G, Fernández-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother 1985; 28:548-551.
3. Ariza J, Gudiol F, Pallarés R, Viladrich PF, Rufi G, Corredoira J, Miravitlles MR. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. Ann Intern Med 1992; 117:25-30.
4. Hall WH. Modern chemotherapy for brucellosis. Rev Infect Dis 1990; 12:1060-1099.
5. Lubani MM, Dudin KK, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pcdiatr Infect Dis J 1989; 8:75-78.
6. Landinez R, Linares J, Loza E, Martínez-Beltrán J, et al. In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Brucella melitensis. Eur J Clin Microbiol Infect Dis 1992; 11:265-267.
7. García-Rodríguez JA, Mun̄oz-Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993; 37:911-913.
8. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33:277-282.
9. Wildfeuer A, Laufen H, Muller-Wening D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneimittelforschung 1989; 39:755-758.
10. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10:828-833.
11. Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis laboratory. I.N.R.A., Paris, France, 1988.
12. Domingo S, Gastearena I, Díaz R, Gamazo C. Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. J Chemother 1995; 7 (suppl. 4): 29-31.
13. Barry AL, Jones RN, Thornsberry C. The in vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268), erythromycin, roxithromycin and clindamycin. Antimicrob Agents Chemother 1988; 32: 752-754.
14. Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-636.